| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0007100 | Exon-Exon | chr6:4892378-4892558 | chr6:4892144-4892324 | 181 nt | 0.6464 |
| hsa_CDYL_0007200 | Exon-Exon | chr6:4892531-4937971 | chr6:4892297-4937737 | 173 nt | 0.4855 |
| hsa_CDYL_0007500 | Intron-Intron | chr6:4894107-4897442 | chr6:4893873-4897208 | 354 nt | 0.4407 |
| hsa_CDYL_0007300 | Intron-Intron | chr6:4894107-4898505 | chr6:4893873-4898271 | 250 nt | 0.3880 |
| hsa_CDYL_0007600 | Intron-Intron | chr6:4894107-4906617 | chr6:4893873-4906383 | 275 nt | 0.4364 |
| hsa_CDYL_0007700 | Intron-Intron | chr6:4894107-4906858 | chr6:4893873-4906624 | 251 nt | 0.4104 |
| hsa_CDYL_0007400 | Intron-Intron | chr6:4894107-4907115 | chr6:4893873-4906881 | 250 nt | 0.3440 |
| hsa_CDYL_0007800 | Intron-Intron | chr6:4894107-4909043 | chr6:4893873-4908809 | 301 nt | 0.4684 |
| hsa_CDYL_0007900 | Intron-Intron | chr6:4894107-4912360 | chr6:4893873-4912126 | 280 nt | 0.4821 |
| hsa_CDYL_0008000 | Intron-Intron | chr6:4894107-4919203 | chr6:4893873-4918969 | 211 nt | 0.3791 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].